| HOME >> BIOLOGY >> TECHNOLOGY |
SARASOTA, Fla., March 10 /PRNewswire/ -- Lakewood-Amedex, Inc., (L-A), the anti-infectives biopharmaceutical company developing a unique portfolio of anti-bacterial and anti-viral products including NuBiotics(R), a novel family of synthetic anti-bacterial compounds, announced today the appointment of William J. Robison, a former Pfizer senior executive, to the company's Board of Directors.
Mr. Robison most recently was an Executive Vice President of Pfizer, Inc. until he retired in 2001. He joined Pfizer, Inc. in 1961 and served within Pfizer's pharmaceutical sales organization to become Senior Vice President of Sales for Pfizer Labs. He was subsequently named General Manager for Pratt Pharmaceuticals and in 1992 was named President of Pfizer's Consumer Healthcare Group and made a Pfizer Corporate Officer. In 1996 he joined Pfizer's Corporate Management Committee and was promoted to the position of Executive Vice President and Head of Worldwide Corporate Employee Resources.
Mr. Robison currently serves as a director of several healthcare companies and is also on the Board of Trustees of the
Steve Parkinson, L-A's President and Chief Executive Officer, commented, "We're delighted to have this highly experienced and respected pharmaceutical professional on our Board. Mr. Robison broadens our existing scientific and medical expertise and he will be especially valuable as we start to develop strategic collaborations with potential large pharmaceutical partners."
Mr. Robison said, "It is a great pleasure to be a part of an exciting and growing company like Lakewood-Amedex. Its broad anti-bacterial and targeted anti-viral products hold great promise for the healthcare industry and could save n
'/>"/>
| SOURCE Lakewood-Amedex, Inc. Copyright©2009 PR Newswire. All rights reserved |